Our new 2022 RealRate ratings for the U.S. Pharma Industry are now out!
The Top 20 Pharma companies are as follows:
The top 3 companies in order are Agios Pharmaceuticals, Ovid Therapeutics and Omeros.
They had Economic Capital Ratio figures of 1002%, 665% and 506% respectively. The market average is -276%. All 3 companies did well due to their superior Net Income scores.
118 companies received our ‘Top Rated’ award.
The next 20 companies in the ranking are as follows:
The pharmaceutical market in the United States is enormous, accounting for approximately 45% of the global market, and around 22% of production globally. U.S. pharmaceuticals output and sales remain strong during 2022, largely driven by the continuing global vaccination rollout, and also huge demand for both essential and non-essential medical treatments.
The incredible thing we do here at RealRate is to deliver fair and independent ratings, bringing together expert knowledge with cutting edge artificial intelligence.
It’s our AI model that computes the all-important Economic Capital Ratio figure. This is completely unbiased and uses only audited public data.
We are fair, explainable, and above all, avoid any conflicts of interest.
We are revolutionising the ratings industry one ranking at a time.
Main photo source: https://openai.com/dall-e-2/